Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I
a study on MPS I
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Oakland, California and other locations
- Dates
- study startedestimated completion:
- Principal Investigator
- Paul Harmatz
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Sangamo Therapeutics
- ID
- NCT02702115
- Phase
- Phase 1
- Lead Scientist
- Paul Harmatz
- Study Type
- Interventional
- Last Updated
- February 5, 2018